Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dermata Therapeutics, Inc. (DRMA) SEC filings page on Stock Titan aggregates the company’s official U.S. regulatory disclosures, offering a structured view of how this dermatology-focused biotechnology issuer reports its activities. Dermata uses SEC filings to describe progress with its Spongilla technology platform, clinical programs such as XYNGARI™ and DMT410, financing arrangements, and key corporate decisions.
Current and prospective investors can review Form 8-K filings for material events, including press release disclosures about clinical trial data, strategic pivots, financing transactions, and significant agreements. For example, Dermata has filed 8-Ks discussing its corporate updates and financial results, the presentation of Phase 3 STAR-1 acne data, increases to its at-the-market offering capacity, and the termination of a License Agreement with Villani, Inc. related to sponge-based pharmaceutical products.
Annual Form 10-K and quarterly Form 10-Q reports (when available) provide more comprehensive information on Dermata’s business, risk factors, financial statements, and details on its lead programs XYNGARI™ and DMT410. These filings also reference key licensing arrangements, intellectual property, and the company’s shift toward over-the-counter pharmaceutical dermatology products.
On Stock Titan, Dermata’s filings are complemented by AI-powered summaries designed to clarify complex sections of lengthy documents, such as clinical trial descriptions, capital structure changes, and agreement terms. Users can quickly understand the implications of new 8-Ks, 10-Qs, and 10-Ks without reading every page, while still having direct access to the full text filed with the SEC. This page also surfaces information relevant to equity offerings and at-the-market programs, helping readers follow how Dermata funds its dermatology pipeline and OTC initiatives.
Dermata Therapeutics insider Gerald T. Proehl reports beneficial ownership of 694,576 shares of common stock, representing 19.6% of the company’s outstanding shares as of January 29, 2026. This percentage is based on 3,549,393 shares outstanding on that date.
The stake includes 24 shares and options for 1,763 shares held directly, 79,950 shares and 11 warrant shares held through Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts where he is trustee. Some additional options and warrants are excluded because they do not vest or become exercisable within sixty days or require stockholder approval.
The filing states there have been no purchases or sales of Dermata common stock or related convertible securities by Proehl or entities he controls since the prior amendment filed on January 8, 2026.
Dermata Therapeutics, Inc. filed a resale prospectus covering up to 6,207,730 shares of common stock for selling stockholders. This includes 1,484,312 shares already issued, 537,750 pre-funded warrant shares, 2,022,062 Series C warrant shares, 2,022,062 Series D warrant shares, and 141,544 placement agent warrant shares.
The company will not receive proceeds from share resales but may receive cash if warrants are exercised, at $2.04 per share for the Series C and Series D Warrants and $2.55 for the Placement Agent Warrants. Dermata is pivoting from prescription drugs to over-the-counter dermatology products built on its Spongilla technology, with a planned mid‑2026 launch of a once‑weekly topical acne kit using salicylic acid. A 1‑for‑10 reverse stock split became effective on August 1, 2025, and all share figures reflect this adjustment.
Dermata Therapeutics, Inc. filed a prospectus supplement on January 27, 2026 to increase the maximum aggregate offering amount of its common stock issuable under its existing at-the-market offering program with H.C. Wainwright & Co., LLC by an additional $705,000.
The company previously sold $3,454,390 of common stock under the same Sales Agreement and earlier prospectus supplements. The filing also includes a legal opinion from Lowenstein Sandler LLP covering the additional $705,000 of common stock, which is provided as an exhibit.
DRMA is updating its at-the-market stock offering program to allow additional sales of its common stock with an aggregate offering price of up to $705,000 through H.C. Wainwright & Co. under an existing Form S-3 shelf. This amount is in addition to approximately $3,454,390 of common stock previously sold under earlier prospectus supplements. The filing reflects the limits of General Instruction I.B.6 of Form S-3, which restricts primary offerings to no more than one-third of public float in any 12-month period while public float is below $75.0 million. The company reports a public float of about $7,493,999, based on 2,386,624 shares held by non-affiliates as of January 23, 2026, at a reference price of $3.14 per share, and notes that about $1,792,248 of securities have been sold under these limits in the last twelve months.
Dermata Therapeutics, Inc. is registering up to 6,207,730 shares of common stock for resale by existing investors under a Form S-3 registration statement. These shares include 1,484,312 common shares plus shares issuable upon exercise of 537,750 pre-funded warrants, 2,022,062 Series C warrants, 2,022,062 Series D warrants, and 141,544 placement agent warrants, all issued in a December 29, 2025 private placement. Dermata will not receive proceeds from stockholder resales but would receive cash only if the warrants are exercised, which it plans to use for working capital and general corporate purposes.
The company describes a major strategic shift from prescription dermatology to over-the-counter, science-backed products built on its Spongilla technology, with an initial once-weekly topical acne kit targeted for launch in mid-2026. Dermata also notes a 1-for-10 reverse stock split effective August 1, 2025 and highlights Nasdaq listings for its common stock and public warrants under the symbols “DRMA” and “DRMAW.”
Dermata Therapeutics major shareholder Gerald T. Proehl filed Amendment No. 8 to his Schedule 13D reporting updated ownership and recent transactions in Dermata Therapeutics, Inc. common stock. He may be deemed to beneficially own 694,530 shares of common stock, representing 24.7% of the outstanding shares, based on 2,809,753 shares outstanding as of January 7, 2026. This includes 24 shares and options for 1,669 shares held directly, 79,950 shares held by Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts for which he is trustee.
Proehl Investment Ventures LLC separately reports beneficial ownership of 79,950 shares, or 2.8% of the common stock, and is no longer a beneficial owner of more than 5% as of December 23, 2025. The filing describes a December 23, 2025 private placement in which the issuer agreed to sell 1,484,312 shares, pre-funded warrants for up to 537,750 shares, and Series C and Series D warrants for up to 2,022,062 shares each at purchase prices of $2.04 per share and $2.039 per pre-funded warrant.
Through certain trusts, Proehl purchased 612,745 shares and warrants exercisable for 1,225,490 shares in the private placement, subject to beneficial ownership limits of 4.99% or, at the holder’s election, 9.99%. He also received an option for 37,500 shares on January 2, 2026 in his role as Chief Executive Officer, which is not yet counted as beneficially owned.
Dermata Therapeutics director David F. Hale reported a new stock option grant. On 01/02/2026, he was awarded a stock option to buy 2,500 shares of Dermata Therapeutics, Inc. common stock at an exercise price of $2.18 per share.
The option vests in twelve substantially equal monthly installments, with the first installment vesting one month after the grant date, as long as he remains in continuous service through each vesting date. Following this grant, he beneficially owns 2,500 derivative securities directly.
Dermata Therapeutics, Inc. director Kathleen D. Scott reported receiving a grant of stock options. The award covers 2,500 Stock Options (Right to Buy) Dermata common shares at an exercise price of $2.18 per share, with no cash paid at grant. These options were granted on 01/02/2026 and are held directly.
The options will vest in twelve equal monthly installments, with the first installment vesting one month after the grant date and additional portions vesting monthly thereafter, as long as Scott continues to serve the company through each vesting date. The options are scheduled to expire on 01/01/2036, and the filing shows 2,500 derivative securities beneficially owned following this transaction.
Dermata Therapeutics director Andrew Seth Sandler received a grant of stock options for 2,500 shares on January 2, 2026. The options have an exercise price of $2.18 per share and expire on January 1, 2036. They vest in twelve substantially equal monthly installments, starting one month after the grant date, contingent on his continuous service. Following this award, he beneficially owned 2,500 derivative securities directly.